of a reliable biomarker in neurological disease leads to economic burdens of $1.7T in the US and Europe alone and stagnant patient outcomes with no significant improvement in outcomes in the last 30 years. Eysz is using analysis of eye-movements as a biomarker to assess brain health across neurological disorders starting with epilepsy – a disorder characterized by recurrent seizures. After completing a successful clinical study sponsored by the NIH and NSF Eysz will be releasing their first product to diagnose and monitor childhood absence epilepsy in Q3 2023.